KRAS and mucinous neoplasm: Notably, type I tumors evolve slowly and are associated with distinct molecular changes that are rarely found in type II tumors, such as BRAF and KRAS mutations for serous tumors, KRAS mutations for mucinous tumors, CTNNB1 and PTEN mutations for endometrioid tumors.